文献速递临床试验与 GCP流行病学与生物统计

乳腺癌放疗剂量分割的随机对照试验:系统综述与荟萃分析,重点关注副作用与美容效果

Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis.
PubMed 文献 · BMJ · 2024-09-11

该系统综述与荟萃分析纳入35项随机对照试验共20237例患者,比较常规分割、中度大分割和超大分割放疗。中度大分割较常规分割显著降低≥2级急性放射性皮炎风险(RR 0.54,95%CI 0.49-0.61,P<0.001),并改善美容效果和生活质量,肿瘤学结局相当。超大分割与中度大分割的≥2级急性放射性皮炎风险无显著差异(RR 0.85,95%CI 0.47-1.55,P=0.60)。

要点

  • 中度大分割较常规分割降低≥2级急性放射性皮炎风险(RR 0.54,95%CI 0.49-0.61,P<0.001)。
  • 中度大分割改善美容效果和生活质量,肿瘤学结局与常规分割相当。
  • 超大分割与中度大分割的安全性及肿瘤学疗效在短期随访中似乎相似。

核心结论

  • 中度大分割较常规分割安全性更好、美容效果和生活质量更优,肿瘤学结局相当。
  • 比较超大分割与其他分割方案的随机对照试验较少,但其安全性和肿瘤学疗效在短期随访中似乎相似。
  • 鉴于缩短治疗时间、方便患者和潜在成本效益,中度大分割和超大分割在适当临床情况下应考虑为优于常规分割的首选方案,需进一步研究以巩固这些发现。

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid MEDLINE、Embase和Cochrane对照试验中心注册库(自建库至2023年10月23日)。
  • 纳入比较常规分割(每日1.8-2 Gy,总剂量50-50.4 Gy,5-6周)、中度大分割(每次2.65-3.3 Gy,13-16次,3-5周)和/或超大分割(仅5次)的随机对照试验。
  • 从1754项研究中纳入59篇文章代表35项试验,共20237例患者。
  • 两名独立研究者筛选文献并提取数据,使用Cochrane协作网工具评估偏倚风险,采用GRADE方法评估证据质量。
  • 采用随机效应模型计算合并风险比(RR)和风险比(HR)及95%置信区间(CI),使用Cochran Q检验和I²统计量分析异质性,并采用网络荟萃分析整合所有可用证据。

主要发现

  • 21.6%的结局显示低偏倚风险,78.4%存在一些担忧或高偏倚风险,尤其在结局测量方面(47.4%)。
  • 中度大分割对比常规分割的≥2级急性放射性皮炎RR在保乳术后为0.54(95%CI 0.49-0.61,P<0.001),乳房切除术后为0.68(95%CI 0.49-0.93,P=0.02)。
  • 在保乳术和乳房切除术合并人群中,中度大分割较常规分割色素沉着和≥2级乳房萎缩更少,RR分别为0.77(95%CI 0.62-0.95,P=0.02)和0.92(95%CI 0.85-0.99,P=0.03)。
  • 仅在保乳术试验中,色素沉着(RR 0.79,95%CI 0.60-1.03,P=0.08)和乳房萎缩(RR 0.94,95%CI 0.83-1.07,P=0.35)的差异未达统计学显著。
  • 超大分割对比中度大分割的≥2级急性放射性皮炎RR在保乳术和乳房切除术合并患者中为0.85(95%CI 0.47-1.55,P=0.60)。

关键数值与推荐

  • 主要结局为≥2级急性放射性皮炎和晚期放疗相关副作用;次要结局包括美容效果、生活质量、复发和生存指标。
  • 常规分割:每日1.8-2 Gy,总剂量50-50.4 Gy,5-6周。
  • 中度大分割:每次2.65-3.3 Gy,13-16次,3-5周。
  • 超大分割:仅5次。

临床怎么用

  • 作者认为,鉴于缩短治疗时间、方便患者和潜在成本效益,中度大分割和超大分割在适当临床情况下应考虑为优于常规分割的首选方案。
  • 作者指出需进一步研究以巩固这些发现。

局限性

  • 78.4%的结局存在一些担忧或高偏倚风险,尤其在结局测量方面(47.4%)。
  • 比较超大分割与其他分割方案的随机对照试验较少。
  • 超大分割数据较不明确,其安全性和肿瘤学疗效仅在短期随访中似乎相似。
  • 需进一步研究以巩固这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide a comprehensive assessment of various fractionation schemes in radiation therapy for breast cancer, with a focus on side effects, cosmesis, quality of life, risks of recurrence, and survival outcomes. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (from inception to 23 October 2023). STUDY SELECTION: Included studies were randomised controlled trials focusing on conventional fractionation (CF; daily fractions of 1.8-2 Gy, reaching a total dose of 50-50.4 Gy over 5-6 weeks), moderate hypofractionation (MHF; fraction sizes of 2.65-3.3 Gy for 13-16 fractions over 3-5 weeks), and/or ultra-hypofractionation (UHF; schedule of only 5 fractions). DATA EXTRACTION: Two independent investigators screened studies and extracted data. Risk of bias and quality of evidence were assessed using the Cochrane Collaboration's tool and the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach, respectively. DATA SYNTHESIS: Pooled risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random effects model. Heterogeneity was analysed using Cochran's Q test and I2 statistic. Network meta-analysis was used to integrate all available evidence. MAIN OUTCOME MEASURES: The pre-specified primary outcome was grade ≥2 acute radiation dermatitis and late radiation therapy related side effects; secondary outcomes included cosmesis, quality of life, recurrence, and survival metrics. RESULTS: From 1754 studies, 59 articles representing 35 trials (20 237 patients) were assessed; 21.6% of outcomes showed low risk of bias, whereas 78.4% had some concerns or high risk, particularly in outcome measurement (47.4%). The RR for grade ≥2 acute radiation dermatitis for MHF compared with CF was 0.54 (95% CI 0.49 to 0.61; P<0.001) and 0.68 (0.49 to 0.93; P=0.02) following breast conserving therapy and mastectomy, respectively. Hyperpigmentation and grade ≥2 breast shrinkage were less frequent after MHF than after CF, with RRs of 0.77 (0.62 to 0.95; P=0.02) and 0.92 (0.85 to 0.99; P=0.03), respectively, in the combined breast conserving therapy and mastectomy population. However, in the breast conserving therapy only trials, these differences in hyperpigmentation (RR 0.79, 0.60 to 1.03; P=0.08) and breast shrinkage (0.94, 0.83 to 1.07; P=0.35) were not statistically significant. The RR for grade ≥2 acute radiation dermatitis for UHF compared with MHF was 0.85 (0.47 to 1.55; P=0.60) for breast conserving therapy and mastectomy patients combined. MHF was associated with improved cosmesis and quality of life compared with CF, whereas data on UHF were less conclusive. Survival and recurrence outcomes were similar between UHF, MHF, and CF. CONCLUSIONS: MHF shows improved safety profile, cosmesis, and quality of life compared with CF while maintaining equivalent oncological outcomes. Fewer randomised controlled trials have compared UHF with other fractionation schedules, but its safety and oncological effectiveness seem to be similar with short term follow-up. Given the advantages of reduced treatment time, enhanced convenience for patients, and potential cost effectiveness, MHF and UHF should be considered as preferred options over CF in appropriate clinical settings, with further research needed to solidify these findings. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023460249.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lee SF, Kennedy SKF, Caini S, et al. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis. BMJ. 2024. PMID: 39260879. doi:10.1136/bmj-2023-079089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。